Welcome to our dedicated page for Vyne Therapeutics SEC filings (Ticker: VYNE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VYNE Therapeutics Inc. filings document the regulatory record for a clinical-stage biopharmaceutical company developing BET inhibitor therapies for inflammatory and immune-mediated conditions. Form 8-K disclosures include quarterly results, clinical and regulatory updates for Repibresib gel and VYN202, and capital-structure information for VYNE common stock.
The filing record also covers stockholder meeting results, director and governance matters, material-event reports, registered security information, and Nasdaq continued-listing compliance disclosures, including minimum bid price notices and extension communications.
VYNE Therapeutics Inc. declared a special cash dividend in connection with its proposed merger with Yarrow Bioscience. The company estimates an aggregate $16.5 million, or an estimated $0.38 per share, based on 42,989,506 shares and equivalents outstanding as of July 9, 2026. The dividend is payable to holders of record as of July 22, 2026 and will be distributed by the transfer agent after payment on July 23, 2026. Payment and the dividend are conditioned on closing of the Merger, which the company expects to occur on or about July 24, 2026, subject to stockholder approval at a special meeting on July 16, 2026.
VYNE Therapeutics Inc. declared a special cash dividend in connection with its proposed merger with Yarrow Bioscience. The Cash Dividend is estimated at an aggregate $16.5 million, or approximately $0.38 per share, based on 42,989,506 shares of common stock and common stock equivalents outstanding as of July 9, 2026.
The dividend will be payable in cash to stockholders and warrant holders of record as of July 22, 2026. The total amount will be delivered to VYNE’s transfer agent on July 23, 2026 and distributed within a few days, and may be higher or lower than the estimate. Payment is conditioned upon the closing of the merger, which is expected on or about July 24, 2026, following a stockholder vote at a special meeting scheduled for July 16, 2026.
VYNE Therapeutics Inc. chief financial officer Tyler Zeronda reported a routine tax-related share disposition. On June 30, 2026, 3,464 shares of common stock were withheld at $0.6507 per share to cover tax obligations arising from the vesting of restricted stock units. After this withholding, Zeronda directly held 97,434 shares of VYNE common stock, indicating the event was compensation- and tax-driven rather than an open-market sale.
VYNE Therapeutics’ Chief Scientific Officer Stuart Iain had 2,370 shares of Common Stock withheld by the company to cover taxes related to vesting restricted stock units. The shares were valued at $0.6507 each in this tax-withholding disposition.
After this routine, non-market transaction, Iain directly holds 111,349 shares of VYNE Therapeutics Common Stock. The filing reflects compensation-related share withholding rather than an open-market purchase or sale.
VYNE Therapeutics Inc.'s Chief Legal Officer and General Counsel, Mutya Harsch, reported a routine tax-related share disposition. On the vesting of restricted stock units, 3,464 shares of common stock were withheld by the company to cover tax withholding obligations at a value of $0.6507 per share. This was not an open-market trade. After this tax-withholding event, Harsch directly holds 118,434 shares of VYNE common stock.
VYNE Therapeutics president and CEO David Domzalski reported a routine tax-related share disposition. On the vesting of restricted stock units, 12,214 shares of common stock were withheld by the company to cover tax obligations at a price of $0.6507 per share. After this withholding, Domzalski directly holds 426,565 shares of VYNE common stock.
VYNE Therapeutics Inc. proposes to merge with Yarrow Bioscience, Inc. Under the Merger Agreement (amended January 30, 2026), Merger Sub will merge into Yarrow and Yarrow will become a wholly owned subsidiary of VYNE; VYNE will be renamed Yarrow Bioscience, Inc.
The proxy/prospectus estimates an Exchange Ratio of approximately 35.8441 shares of VYNE Common Stock per share of Yarrow Capital Stock (pre-reverse split and subject to adjustment). The Yarrow Pre-Closing Financing is approximately $100.0 million. VYNE currently expects to pay a pre-closing cash dividend aggregating approximately $14.5 million to $16.5 million. VYNE stockholders of record as of June 5, 2026 totaled 33,385,055 shares. The special meeting to approve the proposals is scheduled for July 16, 2026.
VYNE Therapeutics Inc. Schedule 13G: Zhang Xiaofan reports beneficial ownership of 1,873,388 shares of common stock, representing 5.6% of the class as of 06/08/2026. The filer states sole voting and dispositive power over the 1,873,388 shares. The signature on the filing is dated 06/15/2026.